secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001104659-25-025326
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia targets final YUTREPIA approval May 23, 2025; FY 2024 net loss $130.4M
-------------------------------------------------------------------------------

- FY 2024 revenue $14.0M (down from $17.5M) driven by Treprostinil Injection promotion; net loss $130.4M ($1.66/share) vs $78.5M loss prior year.
- FDA tentative approval of YUTREPIA (PAH/PH-ILD) granted Aug 2024; final approval expected after NCI exclusivity expires May 23, 2025.
- HCRx financing amended for up to $100M: $25M received at closing, $50M contingent on first YUTREPIA sale, $25M upon $100M net sales milestone.
- Cash and equivalents $176.5M at Dec 31, 2024, up from $83.7M a year earlier.
- ASCENT study (YUTREPIA in PH-ILD) nearing enrollment completion; L606 (liposomal treprostinil) U.S. open-label study ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925025326/0001104659-25-025326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925025326/tm259683d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-025326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer